Compare PTGX & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | VNT |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.1B |
| IPO Year | 2016 | N/A |
| Metric | PTGX | VNT |
|---|---|---|
| Price | $89.29 | $36.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $86.44 | $46.11 |
| AVG Volume (30 Days) | 886.1K | ★ 1.1M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | N/A | ★ 4.02 |
| EPS | 0.72 | ★ 2.73 |
| Revenue | $209,217,000.00 | ★ $3,043,900,000.00 |
| Revenue This Year | N/A | $2.79 |
| Revenue Next Year | $296.47 | $3.27 |
| P/E Ratio | $124.09 | ★ $13.23 |
| Revenue Growth | N/A | ★ 1.76 |
| 52 Week Low | $33.70 | $27.22 |
| 52 Week High | $93.25 | $43.88 |
| Indicator | PTGX | VNT |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 44.54 |
| Support Level | $83.52 | $35.26 |
| Resistance Level | $90.85 | $36.31 |
| Average True Range (ATR) | 2.63 | 0.77 |
| MACD | -0.33 | 0.29 |
| Stochastic Oscillator | 83.62 | 97.33 |
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.